loading
United Therapeutics Corp stock is traded at $312.23, with a volume of 527.43K. It is up +0.51% in the last 24 hours and up +4.81% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$310.66
Open:
$310
24h Volume:
527.43K
Relative Volume:
0.90
Market Cap:
$14.08B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
12.46
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
-0.29%
1M Performance:
+4.81%
6M Performance:
-13.53%
1Y Performance:
-9.99%
1-Day Range:
Value
$308.26
$315.73
1-Week Range:
Value
$303.59
$317.31
52-Week Range:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Name
United Therapeutics Corp
Name
Phone
(301) 608-9292
Name
Address
1000 SPRING ST, SILVER SPRING, MD
Name
Employee
1,305
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.23 14.21B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.62 67.51B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.52 47.88B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.82 43.42B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.46 20.72B 16.70B -157.13M 1.19B -0.155

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Initiated Cantor Fitzgerald Overweight
Apr-25-25 Downgrade Wells Fargo Overweight → Equal Weight
Apr-21-25 Upgrade BofA Securities Underperform → Neutral
Jul-11-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-12-24 Upgrade Goldman Sell → Neutral
Feb-05-24 Initiated Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Dec-06-22 Initiated UBS Buy
Dec-05-22 Initiated Goldman Sell
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-20-22 Reiterated BofA Securities Underperform
Sep-19-22 Resumed Wedbush Outperform
Feb-11-22 Initiated BTIG Research Neutral
Jul-14-21 Upgrade Argus Hold → Buy
Apr-26-21 Resumed Credit Suisse Outperform
Feb-01-21 Upgrade H.C. Wainwright Neutral → Buy
Sep-14-20 Resumed JP Morgan Overweight
Jun-25-20 Reiterated H.C. Wainwright Neutral
Mar-10-20 Upgrade Jefferies Hold → Buy
Feb-27-20 Upgrade Cowen Market Perform → Outperform
Jan-31-20 Upgrade JP Morgan Neutral → Overweight
Dec-03-19 Initiated BofA/Merrill Underperform
Aug-01-19 Upgrade Jefferies Underperform → Hold
Aug-01-19 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-01-19 Upgrade Credit Suisse Neutral → Outperform
May-17-19 Upgrade UBS Sell → Neutral
May-09-19 Upgrade Credit Suisse Underperform → Neutral
Oct-12-18 Upgrade Standpoint Research Hold → Buy
Aug-08-18 Downgrade Credit Suisse Neutral → Underperform
Apr-03-18 Upgrade Credit Suisse Underperform → Neutral
Feb-22-18 Reiterated Barclays Underweight
Jan-18-18 Resumed Credit Suisse Underperform
Dec-27-17 Reiterated Wedbush Outperform
Apr-27-17 Reiterated Wedbush Outperform
Mar-30-17 Initiated UBS Sell
Mar-16-17 Initiated Credit Suisse Underperform
View All

United Therapeutics Corp Stock (UTHR) Latest News

pulisher
Aug 19, 2025

United Therapeutics stock holds Buy rating at UBS on Tyvaso prospects - Investing.com

Aug 19, 2025
pulisher
Aug 15, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - MSN

Aug 15, 2025
pulisher
Aug 14, 2025

United Therapeutics stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com

Aug 14, 2025
pulisher
Aug 13, 2025

United Therapeutics stock price target raised to $415 from $385 at UBS - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

United Therapeutics stock price target raised to $415 from $385 at UBS By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 12, 2025

United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks

Aug 12, 2025
pulisher
Aug 09, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

Should You Be Adding United Therapeutics (NASDAQ:UTHR) To Your Watchlist Today? - 富途牛牛

Aug 08, 2025
pulisher
Aug 07, 2025

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool

Aug 06, 2025
pulisher
Aug 04, 2025

H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey

Aug 04, 2025
pulisher
Aug 01, 2025

United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan

Aug 01, 2025
pulisher
Aug 01, 2025

Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com

Aug 01, 2025
pulisher
Aug 01, 2025

What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Reports Record Revenue and Growth - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics (UTHR) Price Target Lowered by HC Wainwright & Co. | UTHR Stock News - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Jul 31, 2025
pulisher
Jul 31, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus

Jul 31, 2025
pulisher
Jul 30, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛

Jul 30, 2025
pulisher
Jul 30, 2025

Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com Nigeria

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Logs Growth And Launches Big Buyback - Finimize

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics (UTHR) Misses Q2 Earnings Estimates - Yahoo Finance

Jul 30, 2025

United Therapeutics Corp Stock (UTHR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

United Therapeutics Corp Stock (UTHR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
MAHON PAUL A
EVP & GENERAL COUNSEL
Aug 07 '25
Option Exercise
135.42
11,000
1,489,620
47,781
MAHON PAUL A
EVP & GENERAL COUNSEL
Aug 07 '25
Sale
300.00
11,000
3,299,981
36,781
$135.43
price up icon 0.11%
$10.65
price down icon 0.37%
drug_manufacturers_specialty_generic RDY
$14.51
price up icon 0.62%
$17.91
price up icon 2.40%
$18.46
price down icon 1.81%
Cap:     |  Volume (24h):